Literature DB >> 2960555

Analysis of penicillinase-producing Neisseria gonorrhoeae isolates in Madrid (Spain) from 1983-85.

A Fenoll1, S Berrón, J A Vázquez.   

Abstract

Between April 1983 and December 1985, 576 strains of Neisseria gonorrhoeae were isolated in our laboratory from patients attending Sexually Transmitted Diseases (STD) clinics. Of these, 61 (10.6%) were penicillinase-producing. Studies on these strains by plasmid analysis, auxotyping and serogrouping showed that the predominant type strains harboured the Asian resistance plasmid, were prototrophic, and were of serogroup W II/W III. About half of the strains, both of the African and Asian type, harboured the transfer plasmid. Strains of serogroup W II/W III were less sensitive to tetracycline and cefoxitin than serogroup W I strains.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2960555      PMCID: PMC2249288          DOI: 10.1017/s0950268800067959

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  15 in total

1.  A multiple plasmid-containing Escherichia coli strain: convenient source of size reference plasmid molecules.

Authors:  F L Macrina; D J Kopecko; K R Jones; D J Ayers; S M McCowen
Journal:  Plasmid       Date:  1978-06       Impact factor: 3.466

2.  Auxotypes and serogroups of penicillinase producing and non-producing strains of Neisseria gonorrhoeae isolated in Franceville, Gabon.

Authors:  F Yvert; E Frost; M Guibourdenche; J Y Riou; B Ivanoff
Journal:  Genitourin Med       Date:  1985-04

3.  Penicillinase producing strains of Neisseria gonorrhoeae in Madrid.

Authors:  J Vázquez; A Fenoll; S Berrón; A Téllez; R Bilbao
Journal:  Genitourin Med       Date:  1985-04

4.  Epidemiology of gonorrhoea: serogroup, antibiotic susceptibility and auxotype patterns of consecutive gonococcal isolates from ten different areas of Sweden.

Authors:  D Danielsson; S Bygdeman; I Kallings
Journal:  Scand J Infect Dis       Date:  1983

5.  Spectinomycin-resistant penicillinase-producing Neisseria gonorrhoeae.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1983-02-04       Impact factor: 17.586

6.  Genetic linkage between serogroup specificity and antibiotic resistance in Neisseria gonorrhoeae.

Authors:  S Bygdeman; M Bäckman; D Danielsson; M Norgren
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1982-06

7.  Epidemiology of PPNG infections in Amsterdam: analysis by auxanographic typing and plasmid characterisation.

Authors:  M C Ansink-Schipper; M H Huikeshoven; R K Woudstra; B van Klingeren; G A de Koning; D Tio; F J Schoonhoven; R A Coutinho
Journal:  Br J Vener Dis       Date:  1984-02

8.  Evidence for two distinct types of penicillinase-producing Neisseria gonorrhoeae.

Authors:  P L Perine; C Thornsberry; W Schalla; J Biddle; M S Siegel; K H Wong; S E Thompson
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

9.  Epidemiology of PPNG infections in the Netherlands: analysis by auxanographic typing and plasmid identification.

Authors:  M C Ansink-Schipper; B van Klingeren; M H Huikeshoven; R K Woudstra; M Dessens-Kroon; L J van Wijngaarden
Journal:  Br J Vener Dis       Date:  1984-06

10.  Epidemiology of penicillinase-producing Neisseria gonorrhoeae in Liverpool from 1977 to 1982.

Authors:  O P Arya; E Rees; G C Turner; A Percival; C A Bartzokas; E H Annels; P B Carey; A K Ghosh; A E Jephcott; N A Johnston
Journal:  J Infect       Date:  1984-01       Impact factor: 6.072

View more
  3 in total

1.  Isolate of TET M-containing Neisseria gonorrhoeae (TRNG) in Spain.

Authors:  J A Vázquez; S Berrón; B Menéndez
Journal:  Genitourin Med       Date:  1990-08

2.  Lectins agglutination test as an epidemiological marker for Neisseria gonorrhoeae.

Authors:  J A Vázquez; S Berrón
Journal:  Genitourin Med       Date:  1990-08

Review 3.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.